精锋医疗-B(02675.HK)拟发行人民币股份并启动A股上市，9月11日已提交上市前辅导备案

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility
for the contents of this announcement, make no representation as to its accuracy or completeness and expressly
disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the
contents of this announcement.

Shenzhen Edge Medical Co., Ltd.
深圳市精鋒醫療科技股份有限公司

(A joint stock company incorporated in the People ’s Republic of China with limited liability)

(Stock Code: 2675)

INSIDE INFORMATION
PRELIMINARY PROPOSAL FOR THE PROPOSED ISSUE OF RMB SHARES
This announcement is made by Shenzhen Edge Medical Co., Ltd. (the “Company”) pursuant to
Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong
Kong Limited (the “Listing Rules”) and the Inside Information Provisions (as defined under the
Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws
of Hong Kong).
The board of directors (the “Board”) is pleased to announce that the Company will explore a
preliminary proposal for the proposed issue of RMB shares, and initiate the plan for an initial
public offering and listing of RMB ordinary shares on the A share market (the “Proposed A
Share Listing”). The proposed issue of RMB shares is conditional upon and subject to, among
other things, market conditions, further approval by the Board, approval by the shareholders of the
Company at the general meeting, and approvals from the necessary regulatory authorities.
For the purpose of the Proposed A Share Listing, the Company has engaged a pre-listing tutoring
institution, and filed a registration application for the pre-listing tutoring on September 11, 2026.
As at the date of this announcement, save and except for the information disclosed herein, the
Board has neither approved other plans in relation to the Proposed A Share Listing nor made any
application to the relevant regulatory authorities in the PRC or any other regions in respect of the
Proposed A Share Listing.

1

Shareholders and potential investors of the Company should be aware that there is no
assurance that the Proposed A Share Listing will proceed, and that the Proposed A Share
Listing is subject to the approval of, among others, relevant regulatory authorities and the
shareholders of the Company. Shareholders and potential investors of the Company should
exercise caution when dealing in the shares of the Company. The Company will make further
announcement(s) to disclose any material developments in respect of the Proposed A Share
Listing in accordance with the Listing Rules and other applicable laws and regulations as and
when appropriate. This announcement is for information purposes only and is not intended
to, and does not, constitute, or form part of, an invitation or offer to acquire, purchase or
subscribe for any securities of the Company.
By order of the Board
Shenzhen Edge Medical Co., Ltd.
(深圳市精鋒醫療科技股份有限公司)
Dr. Wang Jianchen
Chairman of the Board and Executive Director
PRC, September 11, 2026

As at the date of this announcement, the Board comprises Dr. Wang Jianchen, Dr. Gao Yuanqian,
and Ms. Wu Mengyuan as executive Directors; Mr. Sheng Li, Mr. Chen Gang, and Mr. Qiu Xiang
as non-executive Directors; and Mr. Yang Fan, Mr. Zhang Guoguang and Mr. Lau Ying Kit as
independent non-executive Directors.

2

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性
或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴
該等內容而引致的任何損失承擔任何責任。

Shenzhen Edge Medical Co., Ltd.
深圳市精鋒醫療科技股份有限公司
（於中華人民共和國註冊成立的股份有限公司）

（股份代號：2675）

內幕消息
擬發行人民幣股份的初步建議
本公告乃由深圳市精鋒醫療科技股份有限公司（「本公司」）根據香港聯合交易所有
限公司證券上市規則（「上市規則」）第13.09(2)條及香港法例第571章證券及期貨條
例第XIVA部項下的內幕消息條文（定義見上市規則）作出。
董事會欣然宣佈，本公司將探究擬發行人民幣股份的初步建議，啟動在A股市場
首次公開發行人民幣普通股及上市的計劃（「建議A股上市」）。建議發行人民幣股
份取決於及受限於（其中包括）市場狀況、董事會的進一步批准、本公司股東於股
東大會上的批准及必要監管機構的批准。
就建議A股上市而言，本公司已委聘上市前輔導機構，並於2026 年9 月11 日提交
上市前輔導的登記申請。於本公告日期，除本文所披露的資料外，董事會尚未批
准有關建議A股上市的其他計劃，亦未就建議A股上市向中國或任何其他地區的相
關監管機構提出任何申請。

1

本公司股東及潛在投資者務須注意，概不保證建議A股上市將予進行，而建議A
股上市須獲得（其中包括）相關監管機構及本公司股東的批准。本公司股東及潛在
投資者在買賣本公司股份時務請審慎行事。本公司將就建議A股上市的重大發展
於適當時候根據上市規則及其他適用法律及法規作出進一步披露。本公告僅供參
考，並不意圖構成或構成收購、購買或認購本公司任何證券之邀請、要約或其一
部份。
承董事會命
深圳市精鋒醫療科技股份有限公司
董事主席兼執行董事
王建辰博士
中國，2026年9月11日

於本公告日期，董事會包括執行董事王建辰博士、高元倩博士及吳夢媛女士；非
執行董事盛利先生、陳剛先生及邱翔先生；及獨立非執行董事楊帆先生、張國光
先生及劉英傑先生。

2